| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6169181 | BOEHRINGER INGELHEIM | Compounds useful to treat retroviral infections |
May, 2014
(9 years ago) | |
|
US6169181 (Pediatric) | BOEHRINGER INGELHEIM | Compounds useful to treat retroviral infections |
Nov, 2014
(9 years ago) | |
| US6231887 | BOEHRINGER INGELHEIM | Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation |
Jul, 2018
(5 years ago) | |
|
US6231887 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation |
Jan, 2019
(5 years ago) | |
| US5852195 | BOEHRINGER INGELHEIM | Pyranone compounds useful to treat retroviral infections |
Jun, 2019
(4 years ago) | |
| US6147095 | BOEHRINGER INGELHEIM | Method for improving the pharmacokinetics of tipranavir |
Oct, 2019
(4 years ago) | |
|
US5852195 (Pediatric) | BOEHRINGER INGELHEIM | Pyranone compounds useful to treat retroviral infections |
Dec, 2019
(4 years ago) | |
|
US6147095 (Pediatric) | BOEHRINGER INGELHEIM | Method for improving the pharmacokinetics of tipranavir |
Apr, 2020
(4 years ago) | |
Aptivus is owned by Boehringer Ingelheim.
Aptivus contains Tipranavir.
Aptivus has a total of 8 drug patents out of which 8 drug patents have expired.
Expired drug patents of Aptivus are:
- US6169181
- US6169181*PED
- US6231887
- US6231887*PED
- US5852195
- US6147095
- US5852195*PED
- US6147095*PED
Aptivus was authorised for market use on 23 June, 2008.
Aptivus is available in solution;oral, capsule;oral dosage forms.
Aptivus can be used as treatment of hiv-1 infection by the co-administration of tipranavir and ritonavir..
The generics of Aptivus are possible to be released after 29 April, 2020.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Dec 23, 2011 |
Drugs and Companies using TIPRANAVIR ingredient
Market Authorisation Date: 23 June, 2008
Treatment: Treatment of hiv-1 infection by the co-administration of tipranavir and ritonavir.
Dosage: SOLUTION;ORAL; CAPSULE;ORAL
APTIVUS family patents
